{
    "nct_id": "NCT02745080",
    "official_title": "A Randomized, Double-blind, Active Control, Multicenter Study to Evaluate the Efficacy at Week 52 of Secukinumab Monotherapy Compared With Adalimumab Monotherapy in Patients With Active Psoriatic Arthritis",
    "inclusion_criteria": "* Diagnosis of PsA classified by CASPAR\n* Rheumatoid factor and anti-CCP antibodies negative\n* Diagnosis of active plaque psoriasis, with at least one psoriatic plaque of >= 2cm diameter or nail changes consistent with psoriasis or documented history of plaque psoriasis\n* Inadequate control of symptoms with NSAIDs\n* Inadequate control of symptoms with a conventional DMARD.\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Pregnant or nursing women\n* Evidence of ongoing infectious or malignant process\n* Previous exposure to any biologic drug for Psoriatic Arthritis or Psoriasis\n* Subjects taking high potency opioid analgesics\n* Ongoing use of prohibited psoriasis treatments/medications\n* Previous treatment with any cell-depleting therapies including but not limited to anti-CD20 investigational agents.",
    "miscellaneous_criteria": "Key"
}